Date |
Announcement |
---|---|
September 19, 2022 |
Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement. Read More |
February 15, 2022 |
Repligen Launches AAV Affinity Resins for Gene Therapy Purification. Read More |
December 16, 2021 | Repligen Acquires BioFlex Solutions, LLC. Read more |
November 5, 2021 |
Repligen Releases Inaugural Sustainability Report. Read More |
September 16, 2021 |
Repligen Announces Agreement to Acquire Avitide Inc. Read More |
September 9, 2021 |
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies |
September 3, 2021 |
Repligen Extends Long Term Supply Agreement with Cytiva for Affinity Ligands. Read More |
2021年6月22日 |
Repligen Corporation Announces Agreement to Acquire Polymem S.A. Read More |
February 8, 2021 |
Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines. Read More |
October 27, 2020 |
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions. Read More |
October 1, 2020 |
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines. Read More |
2020年6月29日 |
Repligen Announces Agreement to Acquire Engineered Molding Technology. Read More |
April 26, 2019 |
Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies. Read More |
Septermber 4, 2018 |
Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors. Read More |
2018年6月28日 |
Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand. Read More |
2018年6月27日 |
Repligen Announces Agreement with Navigo Proteins for the Exclusice Co-Development of Next Generation Affinity Ligands. Read More |
2017年6月23日 |
Repligen Corporation and Spectrum Inc. to Join Forces. Read More |
December 15, 2016 |
Repligen acquires TangenX Technology Corporation. Read More |
October 4, 2016 |
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification. Read More |
April 4, 2016 |
Repligen acquires Atoll GmbH. Read More |
Sondra Newman
Senior Director, Investor Relations
Phone: 781.250.0111
Toll-free: 800.622.2259
Fax: 781.250.0115